Ventyx Biosciences (NASDAQ:VTYX) Earns “Outperform” Rating from Oppenheimer

Ventyx Biosciences (NASDAQ:VTYX)‘s stock had its “outperform” rating restated by research analysts at Oppenheimer in a research report issued on Friday,Benzinga reports. They presently have a $9.00 price objective on the stock, down from their previous price objective of $10.00. Oppenheimer’s price objective indicates a potential upside of 305.41% from the company’s current price.

Several other equities analysts have also recently weighed in on VTYX. Canaccord Genuity Group decreased their target price on shares of Ventyx Biosciences from $15.00 to $14.00 and set a “buy” rating for the company in a research note on Monday, August 12th. HC Wainwright reaffirmed a “neutral” rating and set a $6.00 price objective on shares of Ventyx Biosciences in a research report on Tuesday, October 15th. Finally, Wells Fargo & Company reduced their price objective on shares of Ventyx Biosciences from $16.00 to $11.00 and set an “overweight” rating for the company in a research report on Monday, August 12th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, Ventyx Biosciences has a consensus rating of “Moderate Buy” and a consensus target price of $9.00.

Ventyx Biosciences Trading Down 0.9 %

Shares of NASDAQ VTYX traded down $0.02 during midday trading on Friday, reaching $2.22. The company’s stock had a trading volume of 394,654 shares, compared to its average volume of 2,053,604. Ventyx Biosciences has a fifty-two week low of $1.79 and a fifty-two week high of $11.48. The stock has a market capitalization of $156.89 million, a price-to-earnings ratio of -0.80 and a beta of 0.37. The stock has a 50 day simple moving average of $2.24 and a 200-day simple moving average of $2.85.

Ventyx Biosciences (NASDAQ:VTYX) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.12. As a group, equities analysts anticipate that Ventyx Biosciences will post -2.14 EPS for the current year.

Institutional Investors Weigh In On Ventyx Biosciences

A number of hedge funds and other institutional investors have recently modified their holdings of VTYX. Palumbo Wealth Management LLC acquired a new stake in shares of Ventyx Biosciences during the third quarter worth $26,000. China Universal Asset Management Co. Ltd. raised its holdings in Ventyx Biosciences by 64.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,592 shares of the company’s stock valued at $30,000 after buying an additional 5,310 shares during the last quarter. SG Americas Securities LLC bought a new position in Ventyx Biosciences during the 2nd quarter worth approximately $32,000. The Manufacturers Life Insurance Company raised its holdings in Ventyx Biosciences by 41.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 24,349 shares of the company’s stock worth $56,000 after purchasing an additional 7,096 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in Ventyx Biosciences during the 2nd quarter worth approximately $58,000. Institutional investors and hedge funds own 97.88% of the company’s stock.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.